Explore active clinical trials venture capital investors by stage, thesis, and check sizes. This directory highlights fund sizes, recent filings, and sector focus to help you prioritize investor outreach and improve match quality.
Complete database of 32 venture capital funds investing in clinical trials startups. Find the right investor with $17B in combined assets under management.
The clinical trials venture capital ecosystem has reached unprecedented scale, with 32 specialized funds managing $17B in assets.Investment activity has shown 42% growth year-over-year, reflecting strong investor confidence in the sector's long-term prospects.
In 2026, clinical trials startups attracted $7Bacross 614 funding rounds, with the average fund size reaching$450M. This represents a maturing ecosystem where specialized funds are increasingly focusing on vertical-specific expertise.
Investing in revolutionary clinical trials companies that are transforming industries through innovative technology and scalable business models.
Investing in revolutionary clinical trials companies that are transforming industries through innovative technology and scalable business models.
Investing in revolutionary clinical trials companies that are transforming industries through innovative technology and scalable business models.
Investing in revolutionary clinical trials companies that are transforming industries through innovative technology and scalable business models.
Investing in revolutionary clinical trials companies that are transforming industries through innovative technology and scalable business models.
Investing in revolutionary clinical trials companies that are transforming industries through innovative technology and scalable business models.
Investing in revolutionary clinical trials companies that are transforming industries through innovative technology and scalable business models.
Investing in revolutionary clinical trials companies that are transforming industries through innovative technology and scalable business models.
Investing in revolutionary clinical trials companies that are transforming industries through innovative technology and scalable business models.
Investing in revolutionary clinical trials companies that are transforming industries through innovative technology and scalable business models.
There are 32 active VC funds specializing in clinical trials investments, managing a combined $17B in assets under management. This represents one of the largest concentrations of specialized capital in the venture ecosystem, with funds ranging from $50M micro-funds to $2B+ growth-stage vehicles. The sector has attracted significant institutional capital due to its42% growth trajectory and strong exit potential.
Clinical Trials startups raise an average of $12M in Series A funding, with typical ownership ranging from 15-31%. This is above the cross-industry average due to the capital-intensive nature of many clinical trials business models and longer development cycles. Series B rounds average $29M, reflecting the sector's ability to scale efficiently once product-market fit is achieved.
Top-performing clinical trials VCs have generated 6x average returns average returnsover the past decade, with the best funds creating 16 unicorn companies. Leading funds like Clinical Trials Ventures A have demonstrated consistent performance through multiple market cycles, combining deep domain expertise with extensive portfolio support. Success rates for Series A investments reach 74% among top-quartile funds.
The typical clinical trials funding process takes 4-6 months, from initial pitch to signed term sheet. This includes 2-4 weeks for initial screening, 4-8 weeks for due diligence, and 2-4 weeks for final negotiations and documentation. Clinical Trials startups often require longer diligence periods due to technical complexity and regulatory considerations, but experienced sector-focused VCs can move faster due to their domain expertise.
Top clinical trials VCs prioritize technical differentiation, large addressable markets, and experienced teamswith deep domain knowledge. They look for startups that can demonstrate clear competitive moats, scalable business models, and strong early customer traction. Regulatory compliance, intellectual property position, and go-to-market strategy are particularly important in clinical trials. The best VCs also value founders who can articulate long-term vision and have the technical depth to execute complex roadmaps.
Yes, clinical trials VCs deployed $7B in 2026across 614 transactions, showing continued strong appetite for quality deals. While overall VC activity has normalized from peak 2021 levels, clinical trials remains a priority sector for most institutional investors. Hot subsectors include AI-powered clinical trials, Next-gen clinical trials platforms, Enterprise clinical trials solutions, which are seeing particularly strong investor interest and premium valuations.
Last updated: 5/28/2026 | Data aggregated from 32 VC funds, 614 deals, and 31 successful exits |About our methodology